These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29512532)

  • 1. [Homeostasis and Disorder of Musculoskeletal System.Progress in the treatment of rheumatoid arthritis.].
    Tanaka Y
    Clin Calcium; 2018; 28(3):395-401. PubMed ID: 29512532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current concepts in the management of rheumatoid arthritis.
    Tanaka Y
    Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
    Tanaka Y
    J Biochem; 2015 Sep; 158(3):173-9. PubMed ID: 26152731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.
    Singh S; Singh S
    Int Immunopharmacol; 2020 Sep; 86():106731. PubMed ID: 32590315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tofacitinib for the treatment of rheumatoid arthritis].
    Tanaka Y
    Nihon Rinsho; 2016 Jun; 74(6):974-80. PubMed ID: 27311188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.
    Vaddi K; Luchi M
    Expert Opin Investig Drugs; 2012 Jul; 21(7):961-73. PubMed ID: 22612502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment.
    Walker JG; Ahern MJ; Coleman M; Weedon H; Papangelis V; Beroukas D; Roberts-Thomson PJ; Smith MD
    Ann Rheum Dis; 2006 Dec; 65(12):1558-64. PubMed ID: 16760256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?
    Kour G; Choudhary R; Anjum S; Bhagat A; Bajaj BK; Ahmed Z
    Biochem Pharmacol; 2022 Mar; 197():114929. PubMed ID: 35065024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
    Nakayamada S; Kubo S; Iwata S; Tanaka Y
    BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis.
    Kuuliala K; Kuuliala A; Koivuniemi R; Kautiainen H; Repo H; Leirisalo-Repo M
    Arthritis Res Ther; 2017 Apr; 19(1):75. PubMed ID: 28399940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
    Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
    Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
    Kotyla PJ; Islam MA; Engelmann M
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baricitinib: JAK inhibition for rheumatoid arthritis.
    Gras J
    Drugs Today (Barc); 2016 Oct; 52(10):543-550. PubMed ID: 27910962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.
    MacFarlane LA; Todd DJ
    Int J Rheum Dis; 2014 May; 17(4):359-68. PubMed ID: 24460872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baricitinib for the treatment of rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Rev Clin Immunol; 2016 Sep; 12(9):911-9. PubMed ID: 27427830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression in early rheumatoid arthritis.
    Combe B
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):59-69. PubMed ID: 19233046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.